Renal cell carcinoma (RCC) represents 2-3 % of all cancers, and is responsible for 13,570 annual US deaths.
Durability versus Chronic Treatment
Long before the clinical use of targeted therapies, immunotherapy was extensively studied as a therapeutic approach to mRCC. In nonrandomized clinical trials, high-dose interleukin-2 (HD IL-2) demonstrated durable complete responses, achieving recurrence-free, treatment-free survival exceeding 10 years in around 8 % of patients with advanced or mRCC who were treated. Despite the established benefit of HD IL-2, and that patients progressing through IL-2 generally remain eligible for subsequent targeted therapies, the population treated with immune therapy with IL-2 remains limited. The bases for the limited utilization of HD IL-2 include toxicity, cost, hospital time, and the lack of benefit in the majority of patients. Regarding toxicity, short-term side effects with IL-2 can be contrasted with more chronic but less severe side effects associated with open-ended treatments on targeted therapies. Regarding drug costs, the overall cumulative cost with targeted therapy can be similar or more than treatment with HD IL-2, particularly for the patient with disease features that predict for multiyear survival. Of course, the duration of treatment used, the patient selection, and the fact that IL-2 is followed by targeted therapy in most cases makes comparisons difficult.
Almost all mRCC patients on targeted therapies eventually experience disease progression, with long-term remissions represented only in isolated cases, and not in the larger phase III studies. Increased understanding of the limitations of the targeted therapies over the last few years and recent advances in the cancer immunotherapies in general has led to a resurgence of interest in the investigation of immunotherapy as a major treatment strategy, with HD IL-2 and other approaches such as checkpoint inhibition and vaccination being investigated in the treatment of mRCC. 13, 14 This article will review current research investigating immunologic therapy in mRCC with emphasis on the approved therapy with IL-2.
Immunotherapy as a Therapeutic Approach to Metastatic Renal Cell Carcinoma
For the most part, RCC has not shown a significant response to traditional cytotoxic therapy, and this helped to drive interest in other approaches; immunotherapy is known to result in rare but dramatic responses in some RCC. The observation of mRCC apparently showing spontaneous regression in placebo groups of clinical trials is presumably a result of the isolated events of the host immune response waxing stronger over time. 15 The antigenic features of certain cancers that make them responsive to immunotherapy are poorly understood and are the subject of considerable research. Melanoma is a particularly immunogenic cancer, for which many tumor antigens are well characterized. An enhanced understanding of the differences in antigenic features between mRCC and melanoma would accelerate the development of immunotherapies for mRCC. One potential difference lies in tumor-associated antigens (TAAs) that trigger the cell-mediated immune response. Tumor-infiltrating lymphocytes (TILs) are found in high numbers in RCC tumors; however, they are not directed at TAAs and have not demonstrated clinical efficacy in mRCC, a contrast with the melanoma experiences. Treatment with CD8+ TILs did not improve response rate or survival in RCC patients treated with lowdose IL-2 after nephrectomy. 16 Reasons for lower frequency of clinically useful immune response of the treatment may include a lack of TAA or of more tumor-induced local or systemic immunosuppression. Although preclinical evaluations suggested that adoptive cell transfer (ACT) could be a promising approach in mRCC patients, 17 a recent meta-analysis identified five hindrances to the lack of success of such approaches, including high degree of personalization, unsuitable response assessment criteria, inadequate identification of TAAs, lack of effective combination treatments, and insufficient attention paid to the quality of ACT products. [35] [36] [37] Response rates to treatment with VEGF pathway drugs, in patients with prior IL-2 therapy or prior interferon therapy, appear about the same in nonrandomized, cross-trial comparison to those seen in patients with no prior therapy (see Table 1 ). A direct prospective comparison has not been conducted to address that matter specifically.
The use of HD IL-2 is associated with adverse effects (AEs), mainly because of capillary leak syndrome. [44] [45] [46] Patients with mRCC should therefore be carefully assessed for suitability in terms of cardiovascular and the pulmonary status to undergo treatment with HD IL-2. 48 In a case series where patients were stratified according to histology, the overall response rate was almost doubled in the subgroup of patients with favorable histologic features (less than 10 % papillary features and at least one of: >50 % alveolar/solid or >50 % clear cell features). 47 In an extension of this study (n=103), the overall response rate was 57 % with complete response in 22 %. 49 Basal levels of the immunosuppressive cytokines may also be important: higher C-reactive protein level has been associated with poor survival in mRCC patients treated with HD IL-2.
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The HD (IL-2) 'Select' trial (n=120) was designed to determine if the response in mRCC with favorable predictive features was significantly higher than a historical, unselected population. 51 
New and Emerging Combinatorial Immunotherapeutic Approaches
A summary of agents in clinical development is given in Table 2 .
Combined and Sequential Regimes with High-dose Interleukin-2
Numerous clinical studies are investigating the use of HD IL-2 in combination therapy with bevacizumab 67 and with sorafenib 68 in sequential regimens. 69 The combination of adjuvant 5-fluorouracil, IFN-a, and IL-2 in the adjuvant setting was associated with significant toxicity but no survival benefit. 79 Following the discovery that hydroxychloroquine can enhance the antitumor effect of cancer therapies by inhibiting autophagy-related stress tolerance in tumor cells, 80 an ongoing phase II study is investigating the combination of HD IL-2 and hydroxychloroquine. 71 In addition, genistein may arrest tumor cell growth by various mechanisms including inhibition of cell proliferation, induction of apoptosis, induction of differentiation, and modulation of cell cycle progression. 81 A current phase II trial is investigating the combination of genistein and HD IL-2.
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Immune Checkpoint Inhibition
An enhanced understanding of tumor-host interactions has prompted novel immunotherapeutic strategies for mRCC, and immune checkpoint inhibition has emerged as a potential therapeutic strategy. The lymphocyte protein receptor programmed death-1 is an inhibitory checkpoint receptor that plays a major role in T cell activation (see Figure 2) . 82 
AE = adverse event; CI = confidence interval; CR = complete response; DD = denileukin diftitox; HD IL = high-dose interleukin; IFN = interferon; ORR = overall response rate; OS = overall survival; PFS = progression-free survival; PR = partial response; RR = response rate.
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Denileukin diftitox (DD) is a fusion protein of diphtheria toxin and human IL-2 that depletes cells expressing the CD25 component of the IL-2 receptor, the alpha chain of the high affinity trimer receptor (CD25, CD122, CD132).
In a phase I study, the combination of coordinated DD and then HD IL-2 achieved responses in three of nine patients, with one complete response and no unusual AEs. 91 Another potential approach is inhibition of the cytotoxic T-lymphocyteassociated antigen 4 (CTLA4). Antibodies directed against CTLA4 block the interaction between B7 ligands on APCs and CTLA4 on CD8+ and CD4+
T cells (see Figure 2) . 83 The anti-CTLA4 antibody ipilimumab showed durable partial responses in a phase II clinical study, but was associated with severe toxicities in one-third of patients. 92 An association between immune-related toxicity and responses was observed. Combination with IL-2 did not appear to be synergistic, although responses were observed. 93 Single-agent CTLA4
inhibitors are not currently an area of active clinical investigation in mRCC.
A phase I study assessing the combination of the anti-CTLA-4 antibody tremelimumab plus sunitinib resulted in severe renal toxicity. 94 The soluble lymphocyte-activation gene-3 (LAG-3) protein is an agonist of major histocompatibility complex (MHC) class II-driven DC activation that enhances the expansion of tumor-specific CTLs in vitro. 95 In a phase I, trial of patients with advanced RCC, IMP321, a soluble LAG-3 fusion protein, demonstrated clinical activity without significant toxicity. 74 Targeted immunotherapeutic approached are also in clinical development.
The immunotoxin naptumomab estafenatox (Nap) was developed in an effort to activate and target the patients' own T cells to their tumor, by fusing a superantigen variant that activates T lymphocytes to the Fab moiety of a tumor-reactive monoclonal antibody. However, a recent phase II/III trial of Nap + IFN-a did not meet its primary endpoint.
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Vaccine Immunotherapies
Priming of the immune system can enhance the recognition of tumor antigens and increase the chances of an immune response. However, the investigation of vaccine therapy in mRCC has had mixed success. In a phase II study, patients received cytokine therapy or cytokine therapy plus the vaccine TG4010, which targets the glycoprotein mucin-1 (MUC-1). The vaccine was well tolerated, but conferred no significant OS benefit compared with those treated with cytokines alone. 
Summary and Concluding Remarks
Immunotherapy remains an important therapeutic option for patients The ultimate objective of curing RCC remains challenging, but one may be hopeful that new immune therapies will make this a reachable goal for many mRCC patients. n
